PMID- 7738202
OWN - NLM
STAT- MEDLINE
DCOM- 19950605
LR  - 20201219
IS  - 0021-9738 (Print)
IS  - 0021-9738 (Linking)
VI  - 95
IP  - 5
DP  - 1995 May
TI  - The detection and localization of monocyte chemoattractant protein-1 (MCP-1) in 
      human ovarian cancer.
PG  - 2391-6
AB  - Chemokines may control the macrophage infiltrate found in many solid tumors. In 
      human ovarian cancer, in situ hybridization detected mRNA for the macrophage 
      chemokine monocyte chemoattractant protein-1 (MCP-1) in 16/17 serous carcinomas, 
      4/4 mucinous carcinomas, 2/2 endometrioid carcinomas, and 1/3 borderline tumors. 
      In serous tumors, mRNA expression mainly localized to the epithelial areas, as 
      did immunoreactive MCP-1 protein. In the other tumors, both stromal and 
      epithelial expression were seen. All tumors contained variable numbers of cells 
      positive for the macrophage marker CD68. MCP-1 mRNA was also detected in the 
      stroma of 5/5 normal ovaries. RT-PCR demonstrated mRNA for MCP-1 in 7/7 serous 
      carcinomas and 6/6 ovarian cancer cell lines. MCP-1 protein was detected by ELISA 
      in ascites from patients with ovarian cancer (mean 4.28 ng/ml) and was produced 
      primarily by the cancer cells. Human MCP-1 protein was also detected in culture 
      supernatants from cell lines and in ascites from human ovarian tumor xenografts 
      which induce a peritoneal monocytosis in nude mice. We conclude that the 
      macrophage chemoattractant MCP-1 is produced by epithelial ovarian cancer and 
      that the tumor cells themselves are probably a major source. MCP-1 may contribute 
      to the accumulation of tumor-associated macrophages, which may subsequently 
      influence tumor behavior.
FAU - Negus, R P
AU  - Negus RP
AD  - Biological Therapies Laboratory, Imperial Cancer Research Fund, London, United 
      Kingdom.
FAU - Stamp, G W
AU  - Stamp GW
FAU - Relf, M G
AU  - Relf MG
FAU - Burke, F
AU  - Burke F
FAU - Malik, S T
AU  - Malik ST
FAU - Bernasconi, S
AU  - Bernasconi S
FAU - Allavena, P
AU  - Allavena P
FAU - Sozzani, S
AU  - Sozzani S
FAU - Mantovani, A
AU  - Mantovani A
FAU - Balkwill, F R
AU  - Balkwill FR
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Clin Invest
JT  - The Journal of clinical investigation
JID - 7802877
RN  - 0 (Chemokine CCL2)
RN  - 0 (Chemotactic Factors)
RN  - 0 (Cytokines)
RN  - 0 (DNA Primers)
RN  - 0 (RNA, Messenger)
SB  - IM
MH  - Adenocarcinoma/*metabolism/*pathology
MH  - Animals
MH  - Ascites
MH  - Base Sequence
MH  - Cell Line
MH  - Chemokine CCL2
MH  - Chemotactic Factors/*analysis/*biosynthesis
MH  - Cystadenocarcinoma, Serous/metabolism/pathology
MH  - Cytokines/*analysis
MH  - DNA Primers
MH  - Endometrial Neoplasms/metabolism/pathology
MH  - Epithelium/metabolism/pathology
MH  - Female
MH  - Gene Expression
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization
MH  - Macrophages/pathology
MH  - Mice
MH  - Mice, Nude
MH  - Molecular Sequence Data
MH  - Ovarian Neoplasms/*metabolism/*pathology
MH  - Ovary/cytology/metabolism/pathology
MH  - Polymerase Chain Reaction
MH  - RNA, Messenger/biosynthesis
MH  - Transplantation, Heterologous
PMC - PMC295866
EDAT- 1995/05/01 00:00
MHDA- 1995/05/01 00:01
PMCR- 1995/05/01
CRDT- 1995/05/01 00:00
PHST- 1995/05/01 00:00 [pubmed]
PHST- 1995/05/01 00:01 [medline]
PHST- 1995/05/01 00:00 [entrez]
PHST- 1995/05/01 00:00 [pmc-release]
AID - 10.1172/JCI117933 [doi]
PST - ppublish
SO  - J Clin Invest. 1995 May;95(5):2391-6. doi: 10.1172/JCI117933.